Janssen Announces FDA Approval of Darzalex (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
HORSHAM, Pa., June 27, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 27, 2019 Category: Drugs & Pharmacology Source Type: news
Could Lenalidomide Be a New Standard for High-Risk Smoldering Myeloma?
Results from a second clinical trial examined the use of lenalidomide treatment in patients with high-risk smoldering multiple myeloma, where the standard of care has been observation. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
(University of Texas M. D. Anderson Cancer Center) Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2019 Category: International Medicine & Public Health Source Type: news
Lenalidomide + Rituximab Beneficial in Relapsed/Refractory Non-Hodgkin Lymphoma
The MAGNIFY phase IIIb trial looked at the efficacy and safety of lenalidomide combined with rituximab in relapsed/refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
Lenalidomide/Anti-CD19 Antibody Combo Yields Encouraging Results in Poor-Prognosis DLBCL
Researchers studied the Fc-enhanced, humanized anti-CD19 antibody MOR208 combined with lenalidomide in relapsed/refractory large B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Daratumumab Triplet for First-Line Myeloma, but Questions Remain Daratumumab Triplet for First-Line Myeloma, but Questions Remain
The daratumumab, lenalidomide, and dexamethasone triplet is a new frontline option for patients with multiple myeloma who are not candidates for transplant, but how practice-changing are the data?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 29, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Daratumumab Cuts Risk for Progression in Multiple Myeloma
WEDNESDAY, May 29, 2019 -- For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 29, 2019 Category: Pharmaceuticals Source Type: news
FDA Approves Combo for Indolent Non-Hodgkin Lymphomas FDA Approves Combo for Indolent Non-Hodgkin Lymphomas
Lenalidomide may now be used in combination with rituximab for previously treated follicular lymphoma and previously treated marginal zone lymphoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA approves lenalidomide for follicular and marginal zone lymphoma
Hematology/Oncology News Burs (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 29, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Lenalidomide Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news
FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma
SUMMIT, N.J.--(BUSINESS WIRE) May 28, 2019 -- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) approved Revlimid (lenalidomide) in combination with a rituximab product (R²) for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 28, 2019 Category: Drugs & Pharmacology Source Type: news
Lenalidomide Delays Onset of Multiple Myeloma Lenalidomide Delays Onset of Multiple Myeloma
In patients with both high-risk and intermediate smoldering myeloma, treatment with single-agent lenalidomide significantly delayed progression to full-blown disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 20, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Multiple myeloma: DNA rearrangement may predict poor outcomes
(Emory Health Sciences) In multiple myeloma, Ig lambda translocations may indicate poor outcomes and resistance to immunomodulatory drugs such as lenalidomide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2019 Category: Cancer & Oncology Source Type: news
Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma
In patients with relapsed or refractory indolent non-Hodgkin lymphoma, adding lenalidomide to rituximab improves response, according to a placebo-controlled trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 4, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Moffitt CEO to be inducted into the 2019 Florida Inventors Hall of Fame
President and CEO of Moffitt Cancer Center, Dr. Alan List, is being inducted into the 2019 Florida Inventors Hall of Fame for developing new therapeutic strategies for treating blood cancers.
Internationally recognized for his contributions in the development of more effective treatment strategies for myelodysplasti c syndrome and acute myeloid leukemia, List's work led to the development of lenalidomide, which received approval from the U.S. Food and Drug Administration. The treatment transformed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 27, 2019 Category: Pharmaceuticals Authors: Kelsey Sunderland Source Type: news
